AJP - Endo  AJP: Regulatory, Integrative and Comparative Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (December 16, 2008). doi:10.1152/ajpendo.90691.2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/3/E490    most recent
90691.2008v2
90691.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Windahl, S. H
Right arrow Articles by Ohlsson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Windahl, S. H
Right arrow Articles by Ohlsson, C.
Submitted on August 13, 2008
Revised on November 21, 2008
Accepted on December 12, 2008

The role of the G protein-coupled Receptor GPR30 in the Effects of Estrogen in Ovariectomized Mice

Sara H Windahl1, Niklas Andersson1, Andrei S Chagain2, Ulrika EA Martensson3, Hans Carlsten1, Björn Olde3, Charlotte Swanson1, Sofia Moverare-Skrtic4, Lars Sävendal2, Marie K Lagerquist, L. M. Fredrik Leeb-Lundberg3, and Claes Ohlsson5*

1 The Sahlgrenska Academy at Gothenburg University
2 Karolinska Institutet
3 Lund University
4 Sahlgrenska Hospital
5 Sahlarenska Hospital

* To whom correspondence should be addressed. E-mail: claes.ohlsson{at}medic.gu.se.

In vitro studies suggest that the membrane G protein-coupled receptor GPR30 is a functional estrogen receptor (ER). The aim of the present study was to determine the possible in vivo role of GPR30 as a functional ER primarily for the regulation of skeletal parameters, including bone mass and longitudinal bone growth, but also for some other well-known estrogen-regulated parameters, including uterine weight, thymus weight and fat mass. Three-month-old ovariectomized (ovx) GPR30-deficient mice (GPR30-/-) and wild type (WT) mice were treated with either vehicle or increasing doses of estradiol (E2; 0, 30, 70, 160 or 830 ng/mouse/day). Body composition (bone mineral density (BMD), fat mass and lean mass) was analysed by dual-energy-X ray absorptiometry while the cortical and trabecular bone compartments were analysed by peripheral quantitative computerized tomography. Quantitative histological analyses were performed in the distal femur growth plate. Bone marrow cellularity and distribution were analysed using fluorescence activated cell sorter. The estrogenic responses on most of the investigated parameters, including increase in bone mass (total body BMD, spine BMD, trabecular BMD, cortical bone thickness), increase in uterine weight, thymic atrophy, fat mass reduction and increase in bone marrow cellularity, were similar for all of the investigated E2 doses in WT and GPR30-/- mice. On the other hand, E2 treatment reduced longitudinal bone growth, reflected by decreased femur length and distal femur growth plate height, in the WT mice but not in the GPR30-/- mice compared with vehicle-treated mice. These in vivo findings demonstrate that GPR30 is not required for normal estrogenic responses on several major well-known estrogen-regulated parameters. In contrast, GPR30 is required for a normal estrogenic response in the growth plate.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
C. Ohlsson and L. Vandenput
The role of estrogens for male bone health
Eur. J. Endocrinol., June 1, 2009; 160(6): 883 - 889.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.